Accelrys goes late-stage in R&D software game

Accelrys has fused one of its most recent software acquisitions with its enterprise platform, offering customers in biopharma and other markets an integrated package of software to serve groups from early R&D through product manufacturing. And it's the latest push from the San Diego-based scientific software company ($ACCL) to assist companies in managing data at multiple stages of the product development cycle.

The new integrated software package, called Accelrys Process Management and Compliance Suite, is the result of the company's buyout this year of VelQuest for $35 million in cash. That purchase gave the company software that is used to manage quality control (QC) and manufacturing for science-based organizations, building off the company's offerings used earlier in the process of bringing a new drug or other product to market.

"Companies that rely on science to innovate continue to struggle with quickly and cost-effectively transforming good ideas into successful products," Max Carnecchia, Accelrys' president and CEO, said in a statement.

In related news, Accelrys and Aquavit Pharmaceuticals have joined forces to advance Aquavit's PITO-001 and MAV-403 products. The agreement calls for use of Accelrys' Enterprise Platform to build new medical software for personalized medicine.

- here's the product release
- and the partnership announcement

Related Articles:
Accelrys keeps pace with 13% jump in revenue
Accelrys bulks up software offerings in $35M VelQuest buyout
Accelrys snaps up discovery software from Scynexis

Suggested Articles

The new solution aims to streamline the incorporation of human genomic data into clinical trial designs.

The $58 million financing round represents biopharma industry's growing interest in genomics data.

Clinerion inks a new deal that adds 60 million U.S. patients to its clinical trial patient recruitment system.